Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Qilian International Holding Group Ltd. (QLI) Stock Forecast & Price Prediction China | NASDAQ | Healthcare | Drug Manufacturers - Specialty & Generic
$7.18
+0.03 (0.42%)Did QLI Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Qilian International is one of their latest high-conviction picks.
QLI has shown a year-to-date change of 0.0% and a 1-year change of 0.0%, reflecting flat performance over the past year. Comprehensive analyst forecasts are currently unavailable for QLI. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for QLI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
The following stocks are similar to Qilian International based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Manufactures and distributes pharmaceutical ingredients and products.
The company operates by manufacturing active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD), generating revenue from both direct sales to consumers and supplying these products to pharmaceutical companies. Its diverse product lineup includes licorice-based medicines, veterinary pharmaceuticals, and organic fertilizers, catering to various sectors including healthcare and agriculture.
Incorporated in 2019 and based in Jiuquan, China, the company focuses on leveraging traditional medicine alongside modern agricultural practices. Its offerings also include organic fertilizers aimed at enhancing crop yields, indicating a commitment to sustainability and agricultural productivity.
Healthcare
Drug Manufacturers - Specialty & Generic
298
China
2014
Qilian International Holding Group Ltd. will change its name to BGM Group Ltd. effective October 30, 2024, as announced on October 29, 2024.
The name change to BGM Group Ltd. may impact brand perception and investor confidence, potentially affecting stock performance and market positioning.
Qilian International Holding Group Ltd. (NASDAQ: QLI) announced that its Class A shares will trade under the new ticker symbol "BGM" on the Nasdaq Capital Market starting August 11, 2024.
Qilian's shift to Nasdaq Capital Market and new ticker symbol "BGM" could enhance visibility and liquidity, potentially attracting new investors and impacting stock performance.
Qilian International Holding Group (NASDAQ: QLI) has regained NASDAQ compliance as its Class A shares closed above $1.00 for 10 consecutive days from June 21 to July 9, 2024.
Qilian International's compliance with NASDAQ listing rules may restore investor confidence, stabilize share prices, and enhance market perception, potentially attracting new investments.
Qilian International Holding Group (NASDAQ:QLI) will implement a 1-for-5 reverse stock split effective June 21, 2024, as approved by its board on May 29, 2023.
A 1 for 5 reverse split can signal potential issues with stock price or liquidity, impacting investor sentiment and stock valuations. It may lead to volatility around the effective date.
Qilian International Holdings Group Limited (NASDAQ: QLI) reported challenges due to declining demand and prices for its oxytetracycline products, increasing costs, and stricter environmental standards, impacting profitability.
Qilian's declining demand and rising costs in oxytetracycline production may signal reduced profitability, impacting investor confidence and stock performance.
Qilian International Holding Group (NASDAQ: QLI) received a 180-day extension until July 8, 2024, to meet Nasdaq's minimum bid price requirement of $1.00 per share for compliance.
Qilian International's extension to meet Nasdaq's bid price requirement indicates potential stability, but ongoing compliance issues may affect investor confidence and stock performance.
Analyst forecasts for Qilian International Holding Group Ltd. (QLI) are not currently available. The stock is trading at $7.18.
Analyst ratings for QLI are not currently available. The stock is currently trading at $7.18. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
Price predictions from Wall Street analysts for QLI are not currently available. The stock is trading at $7.18.
The company operates by manufacturing active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD), generating revenue from both direct sales to consumers and supplying these products to pharmaceutical companies. Its diverse product lineup includes licorice-based medicines, veterinary pharmaceuticals, and organic fertilizers, catering to various sectors including healthcare and agriculture.
Price targets from Wall Street analysts for QLI are not currently available. The stock is trading at $7.18.
Price targets from Wall Street analysts for QLI are not currently available. The stock is trading at $7.18.
Analyst ratings for QLI are not currently available. The stock is trading at $7.18.
Stock price projections, including those for Qilian International Holding Group Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.